Sort
82,697 grants matching “vaccine development”
Task X9: Agilvax Phage Display for Multiple Vaccine Candidates
$1,505,999James Richardson · Advanced Bioscience Laboratories, Inc. · N01 · FY2015 · AI
Evaluation of HIV-1 Vaccine Candidates in Macaca mulatta
$1,505,898Lindsay M. Wohlers · Novartis Vaccines And Diagnostics, Inc. · P01 · FY2009 · AI
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
$1,505,858Dan H. Barouch · Beth Israel Deaconess Medical Center · P01 · FY2025 · AI
Immunotoxicity in Humans with Lifetime Exposure in Ocean Pollutants
$1,505,842Philippe Grandjean · Harvard University · · FY2013 · GEO
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
$1,505,841Tina V Hartert · Vanderbilt University Medical Center · U19 · FY2020 · AI
Viral and Host Determinants of Infant and Childhood Allergy and Asthma
$1,505,841Ray Stokes Peebles · Vanderbilt University Medical Center · U19 · FY2020 · AI
Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies
$1,505,564Raiees Ahmad Andrabi · Scripps Research Institute, The · R61 · FY2021 · AI
Enhanced Surveillance for Newly Preventable Diseases (ARI and AGE Surveillance) - Rochester, NY
$1,505,484Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2020 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,505,484Janet A Englund · Seattle Children'S Hospital · U01 · FY2020 · IP
New Vaccine Surveillance Network
$1,505,484John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · IP
Defining Factors Controlling HIV Rebound
$1,505,434Jerome A. Zack · University Of California Los Angeles · P01 · FY2019 · AI
Primate Lentivirus Pathogenesis
$1,505,148Malcolm Martin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Potentiating an Anthrax DNA Vaccine with Electroporation
$1,505,125Ichor Medical Systems, Inc. · R42 · FY2005 · AI
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities
$1,505,020Stephan Bour · Digital Infuzion, Inc. · N01 · FY2024 · AI
Innate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)
$1,504,860Daniel Cesar Douek · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Small-molecule inhibitors of flavivirus entry
$1,504,859Priscilla Li-Ning Yang · Harvard Medical School · U19 · FY2017 · AI
Anti-norovirus protease inhibitors for immunocompromised patients
$1,504,695Raymond F. Schinazi · Emory University · R01 · FY2025 · AI
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
$1,504,603Alon Herschhorn · University Of Minnesota · U01 · FY2022 · AI
Delivery of biologically active nucleic acids to epidermal cells
$1,503,903Roger L Kaspar · Transderm, Inc. · RC2 · FY2009 · AR
Influenza vaccination using a microneedle patch
$1,503,781Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2011 · EB
Career Development
$1,503,709W. Ian Lipkin · Wadsworth Center · U54 · FY2008 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses
$1,503,156Pascal Poignard · International Aids Vaccine Initiative · U19 · FY2011 · AI
NOVEL IMMUNE BASED THERAPIES FOR MULTIPLE MYELOMA
$1,503,053Dana-Farber Cancer Institute · P01 · FY2001 · CA
Virus biology scientific research support component
$1,502,929Beatrice H Hahn · Duke University · UM1 · FY2014 · AI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients
$1,502,393William J Steinbach · Arkansas Children'S Hospital Res Inst · R01 · FY2025 · AI